Blood-Based Biomarkers for Alzheimer’s and Parkinson’s Disease, Volume 191 in the International Review of Neurobiology series, presents current advances and comprehensive reviews on the development and application of circulating biomarkers in neurodegenerative disorders. It brings together contributions from an international panel, highlighting emerging strategies for early detection, diagnosis, and monitoring of Alzheimer’s and Parkinson’s diseases. Chapters explore a wide range of topics, including the Diagnostic Potential of Exosomes in Neurodegenerative Diseases and Cancer, Blood Biomarkers of Oxidative Stress and Mitochondrial Dysfunction in Alzheimer’s and Parkinson’s Diseases, GFAP and the Genetic Code of Astrocyte Activation in Alzheimer’s Disease, and much more.
Additional chapters cover Blood-Based Emerging Biomarkers in Early Detection and Diagnosis of Alzheimer’s Disease, Advances in Nanomaterial-Based Biomarker Detection for Neurodegenerative Diseases, Blood-Based Biomarkers in Alzheimer’s and Parkinson’s Disease: From Molecular Pathology to Therapeutic Potential, Blood-Based Biomarkers and Their Role in AD/PD Diagnosis, The Emerging Landscape of Circulatory Biomarkers in Alzheimer’s Disease, Biofluid-Based Biosensors, Biomarkers of Vascular Dementia and Alzheimer’s Disease, Silent Clues in Blood: Proteomic Approach for Alzheimer’s Disease, and more.
1. Title of Book - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. Series Page - p. iii 6. Copyright - p. iv 7. Contributors - p. xix 8. Chapter One: Comprehensive insights into Alzheimer’s disease: Amyloid-β pathology, tau dysfunction, and neurodegenerative mechanisms - p. 1 9. Chapter Two: Blood biomarkers of oxidative stress and mitochondrial dysfunction in Parkinson’s disease and Alzheimer’s disease - p. 27 10. Chapter Three: Redefining Alzheimer’s disease diagnostics in the age of blood-based biomarkers - p. 61 11. Chapter Four: Circulating biochemical signatures of neurodegeneration in Alzheimer’s disease - p. 91 12. Chapter Five: GFAP and the genetic code of astrocyte activation in Alzheimer’s disease - p. 113 13. Chapter Six: Blood-based emerging biomarkers in early detection and diagnosis of Alzheimer’s disease - p. 145 14. Chapter Seven: Advances in nanomaterial-based biomarker detection for neurodegenerative diseases: Special focus on Alzheimer’s and Parkinson’s disease - p. 175 15. Chapter Eight: Blood-based biomarkers in Alzheimer’s and Parkinson’s disease: From molecular pathology to therapeutic potential - p. 225 16. Chapter Nine: The emerging landscape of circulatory biomarkers in Alzheimer’s disease - p. 275 17. Chapter Ten: Silent clues in blood: Proteomic approach for Alzheimer’s disease - p. 345 18. Chapter Eleven: The clinical utility of blood-based biomarkers of Alzheimer’s disease: Triumphs and pitfalls - p. 403 19. Chapter Twelve: Neurofilament light chain (NfL) as a biomarker for neurodegeneration: Protein biology, detection methods, and clinical applications - p. 447 20. Chapter Thirteen: Peripheral manifestations of nigrostriatal neurodegeneration in Parkinson’s disease - p. 487 21. Chapter Fourteen: Diagnostic potential of exosomes in the neurodegenerative disorders and cancer - p. 509 22. Chapter Fifteen: The microbiota-gut–brain axis in epilepsy: Mechanistic insights and emerging probiotic-based therapeutics - p. 537
Blood-Based Biomarkers for Alzheimer’s and Parkinson’s Disease, Volume 191 in the International Review of Neurobiology series, presents current advances and comprehensive reviews on the development and application of circulating biomarkers in neurodegenerative disorders. It brings together contributions from an international panel, highlighting emerging strategies for early detection, diagnosis, and monitoring of Alzheimer’s and Parkinson’s diseases. Chapters explore a wide range of topics, including the Diagnostic Potential of Exosomes in Neurodegenerative Diseases and Cancer, Blood Biomarkers of Oxidative Stress and Mitochondrial Dysfunction in Alzheimer’s and Parkinson’s Diseases, GFAP and the Genetic Code of Astrocyte Activation in Alzheimer’s Disease, and much more.
Additional chapters cover Blood-Based Emerging Biomarkers in Early Detection and Diagnosis of Alzheimer’s Disease, Advances in Nanomaterial-Based Biomarker Detection for Neurodegenerative Diseases, Blood-Based Biomarkers in Alzheimer’s and Parkinson’s Disease: From Molecular Pathology to Therapeutic Potential, Blood-Based Biomarkers and Their Role in AD/PD Diagnosis, The Emerging Landscape of Circulatory Biomarkers in Alzheimer’s Disease, Biofluid-Based Biosensors, Biomarkers of Vascular Dementia and Alzheimer’s Disease, Silent Clues in Blood: Proteomic Approach for Alzheimer’s Disease, and more.
1. Title of Book - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. Series Page - p. iii 6. Copyright - p. iv 7. Contributors - p. xix 8. Chapter One: Comprehensive insights into Alzheimer’s disease: Amyloid-β pathology, tau dysfunction, and neurodegenerative mechanisms - p. 1 9. Chapter Two: Blood biomarkers of oxidative stress and mitochondrial dysfunction in Parkinson’s disease and Alzheimer’s disease - p. 27 10. Chapter Three: Redefining Alzheimer’s disease diagnostics in the age of blood-based biomarkers - p. 61 11. Chapter Four: Circulating biochemical signatures of neurodegeneration in Alzheimer’s disease - p. 91 12. Chapter Five: GFAP and the genetic code of astrocyte activation in Alzheimer’s disease - p. 113 13. Chapter Six: Blood-based emerging biomarkers in early detection and diagnosis of Alzheimer’s disease - p. 145 14. Chapter Seven: Advances in nanomaterial-based biomarker detection for neurodegenerative diseases: Special focus on Alzheimer’s and Parkinson’s disease - p. 175 15. Chapter Eight: Blood-based biomarkers in Alzheimer’s and Parkinson’s disease: From molecular pathology to therapeutic potential - p. 225 16. Chapter Nine: The emerging landscape of circulatory biomarkers in Alzheimer’s disease - p. 275 17. Chapter Ten: Silent clues in blood: Proteomic approach for Alzheimer’s disease - p. 345 18. Chapter Eleven: The clinical utility of blood-based biomarkers of Alzheimer’s disease: Triumphs and pitfalls - p. 403 19. Chapter Twelve: Neurofilament light chain (NfL) as a biomarker for neurodegeneration: Protein biology, detection methods, and clinical applications - p. 447 20. Chapter Thirteen: Peripheral manifestations of nigrostriatal neurodegeneration in Parkinson’s disease - p. 487 21. Chapter Fourteen: Diagnostic potential of exosomes in the neurodegenerative disorders and cancer - p. 509 22. Chapter Fifteen: The microbiota-gut–brain axis in epilepsy: Mechanistic insights and emerging probiotic-based therapeutics - p. 537
